INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.79 USD | +0.86% |
|
+0.84% | -7.96% |
| 05-23 | Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target | MT |
| 05-21 | Incyte Acquires 2 Office Buildings in Delaware | MT |
| Sales 2024 * | 4.09B 321B | Sales 2025 * | 4.52B 354B | Capitalization | 12.99B 1,020B |
|---|---|---|---|---|---|
| Net income 2024 * | 759M 59.58B | Net income 2025 * | 963M 75.59B | EV / Sales 2024 * | 2.24 x |
| Net cash position 2024 * | 3.83B 301B | Net cash position 2025 * | 5.41B 424B | EV / Sales 2025 * | 1.68 x |
| P/E ratio 2024 * |
17.8
x | P/E ratio 2025 * |
14.4
x | Employees | 2,524 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on Incyte Corporation
More recommendations
More press releases
More news
| 1 day | +0.86% | ||
| 1 week | +0.84% | ||
| 1 month | +9.16% | ||
| 3 months | -2.13% | ||
| 6 months | +6.98% | ||
| Current year | -7.96% |
1 week
56.41
57.98
1 month
52.7358.93
Current year
50.3567.37
1 year
50.2767.37
3 years
50.2788.26
5 years
50.27110.37
10 years
43.86153.15
| Managers | Title | Age | Since |
|---|---|---|---|
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 12/01/14 |
| Director of Finance/CFO | 53 | 10/02/19 | |
Steven Stein
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/03/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 31/12/00 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 15/12/19 |
| Director/Board Member | 70 | 19/01/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.55% | 254 M€ | +13.69% | - | |
| 2.94% | 1 M€ | -.--% | - | |
| 2.88% | 0 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 57.79 | +0.86% | 5,049,814 |
| 30/05/24 | 57.3 | +0.67% | 2,254,712 |
| 29/05/24 | 56.92 | -0.58% | 4,190,473 |
| 28/05/24 | 57.25 | -0.10% | 2,276,796 |
| 24/05/24 | 57.31 | -0.24% | 1,966,856 |
Delayed Quote Nasdaq, May 31, 2024 at 09:00 pm
More quotes
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
10/06/2024
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
57.79
USD
Average target price
72.8
USD
Spread / Average Target
+25.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.96% | 12.99B | |
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| +63.05% | 26.47B | |
| -22.14% | 14.25B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B | |
| -17.66% | 7.32B | |
| +88.73% | 7.14B |
- Stock Market
- Equities
- INCY Stock
